OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FOSTER CITY, Calif., Feb. 15, 2017 -- PointCross Life Sciences came out of stealth mode with its Xbiom™ Insights solution for Clinical Biomarker research. With two clients deployed, PointCross is now acquiring new pharma and biotechnology companies who are pursuing precisely targeted therapies in oncology, central nervous system, and cardiovascular. Having proven the capability and value to researchers over the past year, the company has now formally launched its Xbiom™ big data platform.
“Semantically integrating four normally disconnected data sources – clinical data, biomarker data, bio-sample availability, and bioinformatics registry data – into a single point from where researchers can search, stratify cohorts, correlate and analyze clinical findings against biomarkers in minutes is a paradigm changing capability for both big pharma as well as smaller biotech companies,” says Dr. Suresh Madhavan, CEO at PointCross.
The Xbiom™ platform is built on a proven stack of big data technologies, including PointCross' underlying Orchestra® technology with a robust big data stack that is serving the pharmaceutical industry with its petabyte scale. This stack includes Hadoop HDFS, Spark, Cassandra, Lucene/SOLR, and Hive that support the Orchestra® ontology, collaboration, Role Based Access Control and Semantic Data Exchange engines. It is available for big pharma who need users and applications to access the data within Xbiom™. It is also available as a SaaS solution, suitable for smaller biotech firms.
The Xbiom™ platform serves the R&D and Regulatory needs in both non-clinical and clinical development lifecycle as well as biomarker R&D to support translational and precision medicine development. In addition to the Xbiom™ Insights-Clinical Biomarker solution, PointCross also offers Xbiom™ Insights-Nonclinical, Xbiom™ Regulatory-Clinical, and Xbiom™ Regulatory-Nonclinical solutions.
About PointCross Life Sciences
PointCross Life Sciences provides the life sciences industry with data management, analytics and visualization solutions that reduce risks, improve data quality, shorten time to market, and generate better insights from R&D and regulatory data. We are a strategic solution provider to the FDA and to several major Biopharma companies. PointCross was recognized in 2013 as one of Gartner’s Cool Vendors in Life Sciences.
Press Contact: Kunaal Madhavan, Marketing at PointCross Life Sciences www.pointcrosslifesciences.com [email protected]
